东星医疗：拟支付现金购买武汉医佳宝生物材料有限公司90%的股权

Core Viewpoint - Dongxing Medical announced plans to acquire 90% of Wuhan Yijiaobao Biological Materials Co., Ltd. through cash payment, which, if successfully executed, will make Wuhan Yijiaobao a subsidiary of the company [1] Group 1: Transaction Details - The transaction is expected to constitute a major asset restructuring as defined by the "Measures for the Administration of Major Asset Restructuring of Listed Companies" [1] - The acquisition does not involve the issuance of shares by the listed company, nor does it constitute a related party transaction [1] - The transaction will not lead to changes in the controlling shareholder or actual controller of the listed company [1]